Proposed Consolidation of Civilian Suspension and Debarment Offices
Client Alert | less than 1 min read | 02.12.13
On February 7, Chairman Issa of the House Oversight Committee released a discussion draft of legislation that would consolidate more than forty civilian agency suspension and debarment offices and functions into one, centralized "Board of Civilian Suspension and Debarment" in GSA on October 1, 2014. The draft Stop Unworthy Spending Act, or SUSPEND Act, would also permit the newly formed board to enter into agreements to perform suspension and debarment activities for entities other than civilian agencies; consolidate the procurement and non-procurement regulations; require heightened public availability to proceedings and administrative agreements; and provide an expedited process for appropriate matters.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
